Skip survey header

OELVs - Companies

Introduction

Risk & Policy Analysts Ltd (RPA), together with FoBiG, Milieu, and EPRD, have been contracted by the European Commission (DG Employment, Social Affairs and Inclusion) to support the evaluation of a possible amendment of Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work (hereinafter referred to as the CMD).
 
The preventive and protective measures established by the CMD include the Occupational Exposure Limit Values (OELVs) set out in Annex 3 of the Directive.  OELVs are implemented at the national level by means of Occupational Exposure Limits (OELs) which must be at least as stringent as the OELVs in the CMD.  To date, the CMD has established OELVs for three chemical agents (benzene, vinyl chloride monomer and hardwood dusts).
 
In order to adapt the CMD to changes in scientific knowledge and technical progress, it is the intention of the Commission to submit a proposal to the Council and European Parliament, which, amongst other things, may introduce new or revised OELVs for a number of chemical agents, including (but not limited to) the seven chemical agents within the scope of this study.  The objective of the study is to assess the impacts of prospective OELVs for chromium VI compounds, 1,3-butadiene, acrylamide, ethylene oxide, 1,2-epoxypropane, bromoethylene, and a revised OELV for vinyl chloride monomer.  A summary of the OELVs that are being considered is provided below.
 
Chemical agent CAS number OELV under consideration (mg/m^3 8 hr TWA, unless stated otherwise)
1,3-Butadiene 106-99-0 2.25
Acrylamide 79-06-1 0.07
Ethylene oxide 75-21-8 1.83
1,2-Epoxypropane (methyloxirane) 75-56-9 2.41
Bromoethylene 593-60-2 4.37
Vinylchloride monomer 75-01-4 1ppm
Cr(VI) compounds   Examples include: Chromium trioxide 1333-82-0 Four options are being assessed:
Option A: 0.025
Option B: 0.015
Option C: 0.010
Option D: 0.005
Sodium dichromate 10588-01-9
Potassium dichromate 7778-50-9
Potassium hydroxyoctaoxodizincatedichromate 11103-86-9
Strontium chromate 7789-06-2
Dichromium tris(chromate) 24613-89-6
Lead Chromate 7758-97-6
Sodium chromate 7775-11-3
Chromic acid 13530-68-2, 7738-94-5
Ammonium dichromate 7789-09-5
Lead chromate molybdate sulphate red (C.I. Pigment Red 104) 12656-85-8
Lead sulfochromate yellow (C.I. Pigment Yellow 34) 1344-37-2
Pentazinc chromate octahydroxide 49663-84-5
Potassium chromate 7789-00-6
Ammonium chromate 7788-98-9
Barium chromate 10294-40-3
Chromium (VI) chloride 14986-48-2
Chromyl chloride 14977-61-8
Zinc chromate 13530-65-9
Basic lead chromate orange 1344-38-3
Bis(triphenylsilyl) chromate 1624-02-8
Cadmium chromate 14312-00-6
Copper chromate 13548-42-0
Diiron tris(chromate) 10294-52-7
Lithium dichromate 13843-81-7
Lithium chromate 14307-35-8
Magnesium Chromate 13423-61-5
Pyridinium chlorochromate 26299-14-9
Pyridinium dichromate 20039-37-6
Silver chromate 7784-01-2
Zinc dichromate 14018-95-2
 
Corrigendum/clarification 12th May 2016: All limits being considered are expressed as 8 hour TWA.

The objective of the study is to collect data and information feeding into the assessment of the impacts of the OELVs set out above and, in particular, the evaluation of potential impacts on competitiveness and SMEs.  This survey is aimed at companies that may experience impacts if the OELVs under consideration were to be adopted, i.e. primarily producers and users of the relevant chemical agents.

Responses to this questionnaire will be handled in the strictest confidence and will only be used for the purposes of this study. In preparing our reports for the Commission (which, subsequently, may be published), care will be taken to ensure that specific responses cannot be linked to individual companies. If you have specific concerns about how your views will be treated, you can contact us and we will be happy to discuss your concerns.
 
The original deadline for survey completion (18th May) has now been extended to the 31st May 2016 to allow all relevant companies to participate in the consultation.  If you have any questions about the consultation or study more generally, please contact Daniel Vencovsky (daniel.vencovsky@rpaltd.co.uk or +44 (0)1508 528 465).